Traws Pharma logo

Traws PharmaNASDAQ: TRAW

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$13.65 M
-80%vs. 3y high
21%vs. sector
-vs. 3y high
-vs. sector
-259%vs. 3y high
4%vs. sector
-80%vs. 3y high
93%vs. sector

Price

regular market | Thu, 21 Nov 2024 14:30:00 GMT
$4.51+$0.24(+5.62%)

Dividend

No data over the past 3 years
$57.00 K$60.00 K
$57.00 K-$8.47 M

Analysts recommendations

Institutional Ownership

TRAW Latest News

Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results
globenewswire.com14 November 2024 Sentiment: POSITIVE

NEWTOWN, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral diseases, today outlined recent business updates and reported unaudited financial results for the third quarter ended September 30, 2024.

Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil
globenewswire.com08 October 2024 Sentiment: POSITIVE

Investigational agent in development as a one dose treatment or prevention of seasonal and pandemic influenza A dose ranging, Phase 1 study in healthy volunteers demonstrated positive tolerability results and plasma levels in the predicted therapeutic window, enabling selection of Phase 2 dose Preclinical data showed potent inhibition of drug-resistant and bird influenza viruses Phase 2 study expected to begin in H1 2025 Improved therapy is an important need for both seasonal and pandemic flu NEWTOWN, Pa., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of respiratory viral diseases, today announced positive topline Phase 1 safety and pharmacokinetic results for its investigational one-dose influenza (flu) therapy, tivoxavir marboxil (tivoxavir).

Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor
globenewswire.com30 September 2024 Sentiment: POSITIVE

Ratutrelvir was well-tolerated for 10 days and achieved consistent plasma levels in the predicted therapeutic window, without the need for co-administration of ritonavir

Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors
globenewswire.com20 September 2024 Sentiment: POSITIVE

Experienced Life Sciences Executive Brings Strategic Expertise to Support Traws' Further Transformation and Growth

Traws Pharma, Inc. Announces Special Shareholders Meeting Results
globenewswire.com17 September 2024 Sentiment: POSITIVE

Three proposals, including a reverse stock split, were submitted and approved Traws Board subsequently approved a 1-for-25 reverse stock split Traws' shares expected to begin trading on a split-adjusted basis on September 23, 2024 NEWTOWN, Pa., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW) (“Traws” or “the Company”), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of respiratory viral diseases and cancer, today announced the results of the Company's 2024 Special Meeting of Stockholders held on September 16, 2024.

Traws Pharma, Inc. (TRAW) Corporate Update Call Transcript
seekingalpha.com20 August 2024 Sentiment: NEUTRAL

Traws Pharma, Inc. (NASDAQ:TRAW ) Corporate Update Call August 15, 2024 8:00 AM ET Company Participants Bruce Mackle - LifeSci Advisors, IR Werner Cautreels - CEO Mark Guerin - CFO Conference Call Participants Chong Liu - Ladenburg Thalmann Operator Operator Ladies and gentlemen, welcome to Traws Pharma, Inc. Corporate Update Call. At this time all participants are in a listen-only mode.

What type of business is Traws Pharma?

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

What sector is Traws Pharma in?

Traws Pharma is in the Healthcare sector

What industry is Traws Pharma in?

Traws Pharma is in the Biotechnology industry

What country is Traws Pharma from?

Traws Pharma is headquartered in United States

What is Traws Pharma website?

https://www.trawspharma.com

Is Traws Pharma in the S&P 500?

No, Traws Pharma is not included in the S&P 500 index

Is Traws Pharma in the NASDAQ 100?

No, Traws Pharma is not included in the NASDAQ 100 index

Is Traws Pharma in the Dow Jones?

No, Traws Pharma is not included in the Dow Jones index

When was Traws Pharma the previous earnings report?

No data

When does Traws Pharma earnings report?

Next earnings report date is not announced yet